Designing therapeutically effective 5-lipoxygenase inhibitors.
about
5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytesInhibition of tumour growth by lipoxygenase inhibitorsDiscovery of a novel dual fungal CYP51/human 5-lipoxygenase inhibitor: implications for anti-fungal therapyA high throughput screen identifies potent and selective inhibitors to human epithelial 15-lipoxygenase-2Regulatory volume decrease (RVD) by isolated and in situ bovine articular chondrocytes.A potent and selective inhibitor targeting human and murine 12/15-LOX.Discovery of potent and selective inhibitors of human platelet-type 12- lipoxygenase.In vivo rectal inflammatory mediator changes with radiotherapy to the pelvis.Purification and characterization of linoleate 8-dioxygenase from the fungus Gaeumannomyces graminis as a novel hemoprotein.Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs.2-(4-(Biphenyl-4-ylamino)-6-chloropyrimidin-2-ylthio)octanoic acid (HZ52)--a novel type of 5-lipoxygenase inhibitor with favourable molecular pharmacology and efficacy in vivoEffect of a 5-lipoxygenase inhibitor, ZM 230487, on cutaneous allergic inflammation in the guinea-pig.Vascular mode of action of kinin B1 receptors and development of a cellular model for the investigation of these receptors.Structure and ligand based drug design strategies in the development of novel 5- LOX inhibitors.The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field.Pseudoperoxidase investigations of hydroperoxides and inhibitors with human lipoxygenases5-Lipoxygenase inhibitors: a review of recent developments and patents.Intravenous anesthetic propofol binds to 5-lipoxygenase and attenuates leukotriene B4 production.Bacterially induced bone destruction: mechanisms and misconceptions.Neuropeptides in nasal mucosa.On radiation damage to normal tissues and its treatment. II. Anti-inflammatory drugs.Molecular pharmacological profile of a novel thiazolinone-based direct and selective 5-lipoxygenase inhibitor.A fluorescence-based assay for measuring the redox potential of 5-lipoxygenase inhibitors.On the inhibition of 5-lipoxygenase product formation by tryptanthrin: mechanistic studies and efficacy in vivo.Acetyl-11-keto-beta-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity.Inhibition by nitric oxide-donors of human polymorphonuclear leucocyte functions.Inflammation, Cancer and Oxidative Lipoxygenase Activity are Intimately Linked.Melatonin: an endogenous negative modulator of 12-lipoxygenation in the rat pineal gland.Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610.Ascorbic acid 6-palmitate: a potent inhibitor of human and soybean lipoxygenase-dependent lipid peroxidation.Photoactivation of an inhibitor of the 12/15-lipoxygenase pathway.
P2860
Q24320095-04ABEEB0-C263-4D7B-A5C9-6B818DB3DEF8Q24679765-AADEE7CD-4674-424C-9C06-C3729FE607E6Q28534270-D27FB1BA-357D-4FE4-85E2-13FBC1AB8CDDQ28541790-DC419F6A-3F93-4D3E-874D-9FDD5AF2A9F3Q30665503-0C29CA4B-9FDA-424F-A225-90DB03D290DBQ31048087-1003AEF1-CEA0-44FF-B396-1E91765E7549Q33955652-3CFBDE66-4CC9-4FE2-9227-65605DF9D6EFQ34381244-5D9406C9-7294-4EEF-9A0C-7BF3ADD6C5B4Q34384336-BA7C56BF-85A5-4FD9-B0C6-16E44BC114A7Q35132201-032B7780-6A5D-4103-A2B5-86D2CD2D6360Q35287406-3784C62F-E8AA-4A2C-A4FC-538B2A7C2A80Q35874522-C02B95D3-81C6-4596-AFFE-2BBA2331DE34Q36329807-616D45F2-5172-41F6-85A5-C6345506FE7DQ36345885-EFBBFF5B-912A-4238-AE09-5303BB208EA0Q37016080-A249703C-B20D-45DB-98DE-068260B654A6Q37192356-34F552CC-D2D8-4763-9858-EF8257D7A760Q37697795-AF810FD3-672A-4900-B435-8F56E32B01AFQ38772584-9B9DD6B3-EC99-43F3-8CFF-051103444178Q39825282-E442BCDA-2EC9-4093-BED5-13E56396E2BFQ40395439-30E71372-070D-4C34-9B08-0D61F9E02225Q40762827-30FF0948-0028-40A1-B37F-7CFC60799B2FQ41774015-1B0B9EDF-F12C-46D5-A8CF-AF6C7AAB80AEQ41909598-4270FE20-21C4-4426-A7B4-F19A30606B48Q42562996-01D7E76B-D6CE-47C4-948F-0B16FA3A0970Q42705978-91ED5052-10A3-4621-BE51-49F86B66085AQ42920487-47928D59-D6FF-4804-B29E-629DCD8FEC81Q42936280-C4814AFF-6536-467C-B93A-F5B0027B2182Q42995211-F7F16D87-7D71-490E-BAC2-BAA2F42D15A0Q43262386-D938E45D-F211-47C2-A095-EF84DF7C3BB9Q44574681-BBC3DB40-95EA-4915-A0A1-B45D8252A345Q52932484-52AEA3A4-F0D5-489A-A00F-C35C226AD36D
P2860
Designing therapeutically effective 5-lipoxygenase inhibitors.
description
1992 nî lūn-bûn
@nan
1992 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Designing therapeutically effective 5-lipoxygenase inhibitors.
@ast
Designing therapeutically effective 5-lipoxygenase inhibitors.
@en
type
label
Designing therapeutically effective 5-lipoxygenase inhibitors.
@ast
Designing therapeutically effective 5-lipoxygenase inhibitors.
@en
prefLabel
Designing therapeutically effective 5-lipoxygenase inhibitors.
@ast
Designing therapeutically effective 5-lipoxygenase inhibitors.
@en
P1476
Designing therapeutically effective 5-lipoxygenase inhibitors.
@en
P2093
McMillan RM
P304
P356
10.1016/0165-6147(92)90100-K
P577
1992-08-01T00:00:00Z